This is the authors' abstract. We don't add key points for this paper.
To evaluate risk factors associated with development of anti-adalimumab antibodies (AAA) in patients with non-infectious uveitis treated with adalimumab.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bromeo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: